AI in life sciences explained: use cases, benefits & risks

In 2026, AI in life sciences is not a future concept. The life sciences industry has invested heavily in AI across drug discovery, clinical development, regulatory workflows, and medical affairs. But the level of impact varies significantly depending on where and how it is used.

In some areas, AI is improving speed and decision-making in measurable ways. In others, it is still being explored, often with expectations that exceed current capabilities.

If you’re considering using AI across life sciences functions, you need to understand how it is actually applied, what challenges come with it, and where it is delivering reliable value today.

In this guide, we’ll address all that and also guide you on how to implement AI in life sciences.

What AI in life sciences means

When teams talk about AI in life sciences, they are usually referring to multiple, very different technologies at once.

Machine learning models used in drug discovery, natural language processing systems used for literature monitoring, generative AI used for content creation, and computer vision used in imaging analysis all operate differently. They rely on different data types, have different performance characteristics, and fail in different ways.

Treating them as a single category creates confusion and leads to strategies that are too broad to act on.

A more practical way to understand AI in life sciences is to look at it as a set of distinct technologies, each applied to specific problems:

• Machine learning models that predict molecular properties, patient response, or clinical outcomes
• Natural language processing systems that analyze unstructured text such as publications, medical records, or adverse event reports
• Generative AI models that synthesize information, draft content, or design new molecular structures
• Computer vision systems that interpret imaging data such as pathology slides or radiology scans

Each of these has areas where it is already reliable, and areas where it is still experimental.

To use AI in life sciences, you need to first decide which pain point you want to solve, and which technology you want to use.

Applications of AI in life sciences

AI is applied across the life sciences value chain, but the level of maturity and reliability varies by function.

Some applications are already delivering measurable operational value. Others are still being evaluated or remain dependent on further validation.

Drug Discovery and Preclinical Development

AI is most established in early-stage research, particularly in target identification, compound screening, and ADMET prediction.

Machine learning models are used to analyze genomic and molecular data to identify potential drug targets and prioritize compounds. In silico ADMET modeling is one of the more mature applications, helping teams filter out compounds with poor safety or pharmacokinetic profiles before expensive lab testing.

These improvements are meaningful, but bounded. AI accelerates hypothesis generation and prioritization, while experimental validation remains the limiting step.

Clinical Development and Trial Operations

In clinical trials, AI is used to improve patient recruitment, trial design, and operational efficiency.

NLP models analyze electronic health records to identify eligible patients, reducing manual screening effort. Machine learning models are also used to predict site performance and enrollment likelihood.

At a broader level, AI-driven automation across clinical workflows can lead to 35–45% productivity improvements in clinical development functions, depending on implementation and oversight.

Pharmacovigilance and Safety Monitoring

AI is used to monitor and analyze adverse event data across multiple sources.

NLP systems process large volumes of unstructured data, including case reports, clinical notes, and patient-generated content, to identify potential safety signals earlier than traditional methods.

These systems are typically deployed with human oversight, where AI surfaces potential signals and trained professionals validate them before action.

This is one of the more stable AI applications because it focuses on pattern detection at scale rather than decision-making without review.

Regulatory Affairs and Submission Support

AI is increasingly used in regulatory workflows, particularly for document management, consistency checks, and cross-referencing.

NLP tools can review large submission packages, identify inconsistencies, and ensure alignment across documents. This reduces manual effort in preparing complex regulatory submissions.

However, AI-generated scientific content in submissions requires strict validation. Regulatory environments demand traceability, auditability, and human accountability, which limits fully automated use.

Medical Affairs and Scientific Communication

Medical affairs teams use AI for literature monitoring, content structuring, and communication support.

NLP tools help identify and summarize relevant publications across large datasets, while AI-assisted systems help structure presentations, MSL materials, and internal briefings.

The value here is primarily operational. AI reduces the time required to organize and present information, while scientific accuracy remains under human control.

Across these applications, one pattern is consistent.

AI delivers the most reliable value when it is applied to well-defined tasks, supported by high-quality data, and integrated with human review.

At a broader level, the opportunity is large. Analysis of life sciences workflows suggests that 75–85% of workflows contain tasks that can be automated or augmented by AI, indicating significant potential for efficiency gains across the industry

Benefits of AI in life sciences

AI in life sciences creates value when it improves how quickly, accurately, and efficiently decisions are made across the value chain.

The benefits are not about the technology itself, but about what changes in outcomes:

• Reduced time to insights and decisions: AI accelerates data analysis across research, clinical, and operational workflows, allowing teams to move faster from data to actionable conclusions
• Better prioritization of resources: Instead of evaluating all options equally, AI helps identify high-probability candidates, patients, or signals, improving how time and budget are allocated
• Improved efficiency across high-volume workflows: Many life sciences workflows involve repetitive, data-intensive tasks. Many of these  tasks can be automated or augmented by AI, creating significant efficiency gains when applied correctly
• Higher signal detection in large datasets: AI enables analysis at a scale that is not feasible manually, improving the ability to detect patterns, correlations, and early signals across clinical, safety, and research data
• More consistent and standardized outputs: AI-driven systems reduce variability in how data is processed, analyzed, and presented, improving consistency across teams and geographies
• Scalability without proportional increase in effort: AI allows teams to handle larger volumes of data, content, and operations without linearly increasing headcount or manual effort
• Improved use of real-world and unstructured data: AI makes it possible to extract value from sources like clinical notes, publications, and patient-generated data that were previously difficult to use at scale
• Faster iteration and hypothesis testing: AI enables quicker testing of multiple scenarios or hypotheses, allowing teams to refine approaches earlier in the process

These benefits are realized only when AI is applied to well-defined problems, supported by high-quality data, and integrated into existing workflows with proper oversight.

Challenges and risks of AI in life sciences

AI adoption in life sciences is not limited by algorithms.

The constraints are structural, regulatory, and operational. Most AI initiatives fail or underperform not because the models don’t work, but because the environment they operate in is complex and tightly regulated.

Data quality and availability

AI systems are only as reliable as the data they are trained on.

Life sciences data is often fragmented across clinical trial systems, electronic health records, lab systems, and regulatory documents. Differences in formats, missing values, and inconsistent coding reduce model performance in real-world settings.

This is one of the primary reasons why models that perform well in research settings do not always translate into production environments.

Regulatory and compliance constraints

Life sciences operates under strict regulatory frameworks.

AI systems used in clinical, regulatory, or patient-facing contexts must meet requirements for validation, auditability, and explainability. Regulations such as FDA guidance on Software as a Medical Device (SaMD) and frameworks impose strict controls on how data and systems are used.

This limits the use of black-box models in high-stakes decision-making environments.

Accuracy and hallucination risks in generative ai

Generative AI introduces a specific risk in life sciences: plausible but incorrect outputs.

In scientific and medical contexts, even small inaccuracies can lead to incorrect interpretation of clinical data or compliance issues. This is particularly relevant in medical communications, regulatory content, and clinical documentation.

Because of this, AI-generated content must always be reviewed and validated by domain experts before use.

Lack of production-ready validation

Many AI applications are still evaluated in controlled or experimental environments.

Production deployment requires validation on real-world data, integration into workflows, and defined performance thresholds. Without this, systems may not perform reliably at scale.

The gap between research performance and operational performance is a consistent challenge across life sciences AI adoption.

Integration with existing systems

AI systems do not operate in isolation.

They need to integrate with existing infrastructure such as EHR systems, clinical trial platforms, and regulatory workflows. Legacy systems and siloed data environments make this integration complex and resource-intensive.

In many cases, the effort required to prepare data and systems exceeds the effort required to build the AI model itself.

Governance and oversight requirements

AI in life sciences requires structured governance.

This includes defining how models are validated, how performance is monitored, how outputs are reviewed, and how errors are handled. Without this, organizations risk deploying systems that are not reliable or compliant.

Successful AI adoption depends as much on governance as it does on technical capability.

Roadmap to integrate AI in life sciences

Implementing AI in life sciences isn’t like implementing AI in any other sector. For starters, the life sciences industry has a lot of regulatory frameworks we need to follow. Plus, we also need to make sure that the AI systems have high accuracy and don’t hallucinate, especially when dealing with high-risk or sensitive data.

‍

Having a proper AI implementation roadmap can help reduce these risks.

1. Define a specific use case

Start with a clearly defined problem, not a broad objective like “use AI in clinical development” or “apply AI in drug discovery.”

In life sciences, AI delivers value only when the task is tightly scoped. For example, identifying eligible patients from EHR data, summarizing new publications in a therapeutic area, or detecting inconsistencies in regulatory documents are all well-defined problems with measurable outcomes.

A good use case has three characteristics:

• A clear input and output (for example, patient data → eligibility match)
• A measurable success metric (time saved, accuracy, coverage)
• A defined place in an existing workflow

Without this, it becomes difficult to evaluate performance, justify investment, or scale the solution beyond a pilot.

2. Assess data availability and quality

Once the use case is defined, the next question is whether the required data actually exists and whether it can be used reliably.

In life sciences, data is rarely clean or centralized. Clinical trial data, EHR data, molecular data, and regulatory documents often sit in separate systems, use different formats, and follow inconsistent standards.

This creates two challenges:

First, data accessibility. The data needed for the use case may exist, but not in a form that can be easily integrated into an AI system.

Second, data quality. Missing values, inconsistent coding, and fragmented records directly affect model performance. Even well-designed models fail when trained on incomplete or noisy data.

In many implementations, the effort required to prepare and standardize data is greater than the effort required to build the model itself.

3. Select the right AI approach

Once the use case and data are clear, the next step is choosing the appropriate AI modality.

Different types of problems require different approaches:

• Structured prediction problems, such as risk scoring or molecular property prediction, typically use machine learning models
• Text-heavy workflows, such as literature monitoring or adverse event detection, require NLP systems
• Content generation or summarization tasks use generative AI, but with strict validation requirements
• Imaging-based analysis, such as pathology or radiology, relies on computer vision

Choosing the wrong approach creates avoidable failure.

For example, using generative AI where deterministic extraction is required introduces unnecessary accuracy risk. Similarly, applying machine learning without sufficient labeled data limits model performance regardless of algorithm choice.

The decision here is less about which model is most advanced and more about which approach fits the structure of the problem and the data available.

4. Validate on real-world data

Before deploying any AI system, it needs to be tested on data that reflects the environment where it will actually be used.

Performance in research settings or controlled datasets often overestimates real-world performance. In life sciences, variability in data quality, patient populations, and system integration can significantly affect outcomes.

Validation should answer specific questions:

• Does the model perform consistently across different datasets or sites?
• Are performance thresholds clearly defined and met?
• How does the system behave in edge cases or incomplete data scenarios?

In regulated environments, validation is not optional. It must be documented, repeatable, and defensible, especially if the output influences clinical, regulatory, or patient-facing decisions.

5. Integrate into existing workflows

An AI system creates value only if it fits into how work is already done.

This means integrating outputs into existing tools and processes such as EHR systems, clinical trial platforms, safety databases, or regulatory workflows. If users have to switch systems, reformat outputs, or manually bridge gaps, adoption drops quickly.

Integration also defines usability.

For example, identifying eligible patients is useful only if that information can be surfaced directly within clinical workflows or trial recruitment systems. Similarly, literature summaries are valuable only if they align with how medical affairs teams review and use evidence.

The focus here is not just technical integration, but operational fit.

6. Establish human oversight

AI in life sciences operates in environments where decisions have clinical, regulatory, and safety implications.

Because of this, human oversight is a required part of implementation, not an optional safeguard.

This involves defining:

• Where human review is required in the workflow
• What level of expertise is needed for validation
• How discrepancies or errors are identified and handled

For example, in medical communications, AI-generated summaries or drafts must be reviewed against primary sources. In pharmacovigilance, AI-identified safety signals must be validated by qualified professionals before action.

The role of AI here is to assist and scale workflows, not to replace expert judgment.

7. Ensure regulatory and compliance alignment

AI systems used in life sciences must meet the same regulatory standards as any other system involved in clinical, regulatory, or patient-facing workflows.

This includes requirements for:

• Auditability: ability to trace how outputs were generated
• Data integrity: ensuring inputs and outputs are accurate and unaltered
• System validation: documented evidence that the system performs as intended

Frameworks such as FDA guidance on AI/ML and regulations like 21 CFR Part 11 (for electronic records) require that systems are not only functional, but also explainable and defensible.

This becomes especially important when AI influences regulatory submissions, safety reporting, or clinical decisions.

8. Monitor performance and manage drift

AI systems do not remain static after deployment.

Changes in data, workflows, or external conditions can affect model performance over time. This is particularly relevant in life sciences, where patient populations, treatment protocols, and data sources evolve.

Ongoing monitoring should include:

• Performance tracking against defined benchmarks
• Detection of model drift or degradation
• Periodic retraining or recalibration using updated data

Without this, models that initially perform well can become unreliable in production.

9. Start with pilot programs and scale gradually

Large-scale AI rollouts without validation create risk.

Most successful implementations begin with pilot programs focused on a single use case, dataset, or function. This allows teams to test performance, identify integration challenges, and refine workflows before scaling.

Pilots should be designed with clear success metrics, such as time saved, accuracy improvements, or process efficiency.

Once validated, the approach can be expanded to additional use cases or scaled across teams and regions.

10. Build cross-functional alignment

AI implementation in life sciences requires coordination across multiple functions.

Data teams, clinical teams, regulatory teams, medical affairs, and IT all play a role in defining, deploying, and maintaining AI systems.

Misalignment across these groups slows implementation and creates gaps in accountability.

Effective implementation requires:

• Shared understanding of the use case and expected outcomes
• Clear ownership of data, models, and workflows
• Alignment on compliance, validation, and review processes

The future of AI in lifesciences

AI in life sciences is moving from isolated use cases to more integrated, workflow-level applications. The focus is shifting from experimentation to operational deployment.

• From point solutions to integrated workflows: AI is increasingly being applied across connected stages of the value chain, where outputs from discovery, development, and medical functions inform each other rather than operating in silos
• Expansion of multimodal data use: Future systems will combine genomics, clinical data, imaging, and real-world evidence, enabling more comprehensive insights, especially in areas like precision medicine
• Growth of generative AI with stricter controls: Generative AI will expand in content, research, and design workflows, but its use in regulated environments will remain tightly governed with human review and validation
• Stronger regulatory frameworks and governance: Regulatory guidance around AI is evolving, leading to clearer expectations for validation, auditability, and explainability in clinical and regulatory contexts
• Shift toward human-AI collaboration: AI will handle scale, data processing, and structuring tasks, while domain experts remain responsible for interpretation, validation, and decision-making

How Prezent AI supports AI in life sciences 

Across all AI applications in life sciences, one pattern is consistent.

The value of AI depends on how well outputs are interpreted, structured, and communicated to the people making decisions. Clinical insights, trial results, safety signals, and strategic updates only create impact when they are clearly understood by clinicians, payers, regulators, and internal teams.

This is where communication becomes a bottleneck.

AI can generate insights faster, but structuring those insights into clear, audience-specific communication still requires significant effort.

Prezent AI addresses this by focusing on the communication layer of AI in life sciences, combining AI capabilities with structured content systems.

Key capabilities include:

• Astrid AI to convert raw inputs such as clinical data, notes, or documents into structured, audience-specific narratives
• Synthesis and content structuring to organize large volumes of information into clear, logical storylines, helping teams move from data to communication efficiently
• Slide Library and standardized templates with expert-curated formats that ensure consistency, reduce formatting effort, and maintain communication quality across teams
• Story frameworks that guide how scientific and business information is presented, improving clarity and flow across presentations and documents
• Expert-led presentation support (including overnight services and fixed-scope projects) to help teams deliver high-quality, structured communication under tight timelines

In life sciences, where accuracy, compliance, and clarity are non-negotiable, the challenge is not just generating insights.

It is ensuring those insights are communicated in a way that supports real-world decisions.

If you’re scaling AI across life sciences workflows, explore how Prezent AI supports the communication layer. Book a demo or start a free trial.

Frequently asked questions about AI in life sciences

1. How is AI used in life sciences?

AI is used across drug discovery, clinical development, regulatory workflows, pharmacovigilance, and medical affairs. Applications include target identification, patient recruitment, safety monitoring, and scientific content organization, with varying levels of maturity and reliability.

2. What are the most impactful AI applications in pharma today?

The most proven applications include NLP-based patient recruitment (with 30–50% faster enrollment in some cases), molecular property prediction for drug discovery, computer vision in pathology, adverse event detection in pharmacovigilance, and AI-assisted literature monitoring.

3. What are the risks of using AI in life sciences?

Key risks include poor data quality affecting model performance, hallucination in generative AI outputs, regulatory and validation challenges, and lack of governance or oversight in deployment.

4. How is AI changing drug discovery and development?

AI is accelerating target identification, compound screening, and ADMET prediction, improving efficiency in early-stage research. In clinical development, it supports recruitment, biomarker discovery, and safety monitoring, though it has not yet reduced overall clinical attrition rates.

5. What role does AI play in clinical trials?

AI supports patient recruitment, site selection, adaptive trial design, safety monitoring, and biomarker-based patient stratification. These applications improve efficiency but require human oversight and regulatory compliance.

6. How are medical affairs teams using AI?

Medical affairs teams use AI for literature monitoring, structuring scientific content, and synthesizing field insights. AI improves efficiency, but expert review remains essential to ensure accuracy and compliance.